PHOENIX—Discontinuing tyrosine kinase inhibitors (TKIs) is safe for patients with chronic myeloid leukemia (CML) who have mounted a deep and enduring response to the medications, according to research presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023.
Patients receiving a TKI who maintain a deep molecular response for at least two years should be considered for discontinuing therapy, according to Jared Freml, PharmD, BCOP, of Kaiser Permanente